All posts by imreal

PatientIQ Appoints Erik Johnson Vice President of Marketing


News Image

Erik Johnson

“Throughout my career, I have been drawn to opportunities where I can help build teams, scale businesses, and share powerful stories,” said Johnson. “PatientIQ is uniquely positioned to transform care delivery as we know it, and I am excited to help spread that message to the masses.”

PatientIQ, a leader in patient outcomes collection and analysis, today announced the appointment of Erik Johnson as Vice President of Marketing. With more than 20 years of experience driving growth for technology, healthcare, and business-to-business organizations, Johnson will oversee PatientIQ’s strategic marketing and external communication initiatives.

“Throughout my career, I have been drawn to opportunities where I can help build teams, scale businesses, and share powerful stories,” said Johnson. “PatientIQ is uniquely positioned to transform care delivery as we know it, and I am excited to help spread that message to the masses.”

Most recently, Johnson was head of Product Marketing for Verato and previously served as Vice President of Marketing and Chief Commercial Officer for Vigilanz, both business-to-business healthcare technology companies. Johnson also held marketing and business leadership roles in the healthcare divisions of Wolters Kluwer and 3M. At PatientIQ, Johnson will lead the strategy and execution of its brand and product marketing, client communication, and demand generation efforts.

Johnson joins PatientIQ following the company’s $20M Series B raise, the addition of John Gerhardt as Chief Technology Officer, and the continued rapid procurement of real-world evidence, private practice, and enterprise health system customers, such as University of Colorado Medicine and UAB Medicine.

“We are committed to adding the industry’s top talent to our company to support this chapter of growth,” said Matthew Gitelis, CEO, PatientIQ. “Erik’s expertise in expanding brands and businesses will enable PatientIQ to better communicate the power of patient outcomes data and the breadth of our best-in-class offering.”

The cloud-based PatientIQ platform automates the collection, measurement, and analysis of patient-reported outcomes data and leverages a proprietary analytics engine to transform that data into actionable intelligence. Healthcare organizations utilize its insights to benchmark performance, identify best practices and areas of opportunity, and conduct research to push medicine forward. In addition to data analysis, the PatientIQ platform facilitates collaboration, bringing together data-driven clinicians from across the country.

About PatientIQ

PatientIQ is the healthcare technology partner for deriving actionable insights from patient outcomes data. The PatientIQ platform is a cloud-based solution that empowers hospitals, health systems, private practices, and industry partners to systemically collect, measure and analyze patient-reported outcomes data to improve clinical and operational performance. With the single, EHR-integrated platform, leveraging a proprietary analytics engine, healthcare organizations are empowered to continuously capture patient progress and derive intelligent insights that enable better care – without increased administrative burden. In addition to outcomes analysis, the platform facilitates collaboration, bringing together data-driven clinicians from across the country to accelerate research, participate in registries, and push medicine forward. PatientIQ has demonstrated years of experience and a superior ability to transform patient outcomes into actionable intelligence. For more, visit http://www.patientiq.io.

Share article on social media or email:

AssuredPartners Announces Acquisition of AVID Risk Solutions


News Image

AssuredPartners President Randy Larsen said, “As we continue to expand operations in the Wisconsin footprint, we are finding partnerships that will solidify our future. We are pleased to have the team of AVID Risk Solutions join AssuredPartners.”

Marking the 12th acquisition in 2022 for AssuredPartners, AVID Risk Solutions of Madison, WI will join the national broker. The dedicated team of 57 employees will remain under the operational leadership of President and CEO, Brock Ryan and EVP, Ben Shortreed.

Brock Ryan of AVID Risk Solutions stated, “At AVID, we’re committed to listening to each client and help them understand which of our services meets their individual needs, while discovering different approaches that help support their growth and success. We deeply value partnerships and joining AssuredPartners allows us to continue to serve our clients and join a national footprint.”

“The team at AVID Risk Solutions conveys true customer service and dedication to their community, and we are pleased to have them join our growing team in the Great Plains marketplace,” stated Greg LaMair, AssuredPartners Regional President.

AssuredPartners President Randy Larsen said, “As we continue to expand operations in the Wisconsin footprint, we are finding partnerships that will solidify our future. We are pleased to have the team of AVID Risk Solutions join AssuredPartners.”

For more information on AVID Risk Solutions, please visit: http://www.AVIDrisk.com.

###

ABOUT ASSUREDPARTNERS, INC

Headquartered in Orlando, Florida, AssuredPartners is a full-service insurance broker providing commercial insurance, risk management, employee benefits through consulting and services. With over 7,500 employees located in offices throughout North America, London, Belgium and Scotland, AssuredPartners is in the business of building relationships. While cementing powerful, lasting relationships built on trust earned from working openly and honestly with our partners. That’s what we call, Power through Partnership. For more information, call 513-624-1779, email jamie.reinert@assuredpartners.com or visit http://www.assuredpartners.com.

Share article on social media or email:

Houston Board-Certified Emergency Room Physician Answers Your Questions About BA.4 and BA.5 Covid-19 subvariants


Dr. Christopher Langan - SignatureCare Emergency Center, Houston, TX

Dr. Christopher Langan – SignatureCare Emergency Center, Houston, TX

BA.4 and BA.5 are more transmissible because the outer protein that coats the virus, called the spike protein, has changed so it is even better at sticking to the cells in your nose and throat, making it more contagious

As Covid-19 BA.4 and BA.5 subvariants surge throughout the state, Texans have questions about the new variants, their transmissibility, and virulence.

Dr. Christopher Langan, a board-certified emergency room (ER) physician and the Chief Operating Officer (COO) of SignatureCare Emergency Center in Houston, TX, has provided answers to some of the most important questions about the new variants.

Dr. Langan answered several questions about the Covid-19 BA.4 and BA.5 subvariants including what they are, how transmissible and virulent they are, how they are transmitted, and what parents can do to protect their families from contracting the new subvariants.

He said the new subvariants are more contagious but do not appear to cause more severe illnesses.

“The BA.4 and BA.5 are the newest subvariants of the Omicron virus. The spike protein, which is the outer protein on the virus that helps it enter the cell, has changed so it has become more effective at attaching to and entering the human upper respiratory tract. This makes it more contagious, but the virus has not been causing more severe diseases,” he said.

Dr. Langan said the symptoms of BA.4 and BA.5 are similar to earlier Omicron variants and include fever, cough, body aches, sore throat, runny nose, and headaches.

He said the new subvariants are highly transmissible because the outer protein that coats the virus called the spike protein has changed so it is better at sticking to the cells of the nose and throat.

“BA.4 and BA.5 are more transmissible because the outer protein that coats the virus, called the spike protein, has changed so it is even better at sticking to the cells in your nose and throat, making it more contagious.

“More people are getting sick with the virus, but on average the course of illness is much less severe than the initial COVID-19 strains. The virus spends more time in your nose and throat and upper respiratory tract replicating, but is not very good at replicating in the deep lung like the original form of COVID-19.”

Dr. Langan said herd immunity and prior vaccines are not effective against BA.4 and BA.5 because they are different from the earlier variants of Covid-19.

“Unfortunately, the BA.4 and BA.5 subvariants are different enough that the immune system, whether you are vaccinated or had prior COVID, may not work as well against these variants. However, people who have been vaccinated against COVID or have had prior disease will have a better immune response than those who have not had COVID or the vaccination.

“Because the virus is changing, currently herd immunity is not a likely way for us to eradicate COVID in the near future,” he added.

Dr. Langan advised parents to discuss vaccinating their children against Covid-19 with their kids’ pediatrician and make the most informed decisions for their families.

“If parents are reluctant to get children vaccinated, they should discuss the pros and cons with their pediatrician and make the best-informed choice for their family,” he said.

He urged Texans over 50 years old or those with compromised immune systems to get vaccinated and boosted, if they haven’t done so, adding that will decrease their chances of getting severe illness should they become infected with the virus.

Complete answers to your Covid-19 BA.4 and BA.5 questions are available here.

More information about SignatureCare Emergency Center is available at https://ercare24.com.

About SignatureCare Emergency Center

Houston, TX-based SignatureCare Emergency Center owns 24-hour emergency centers throughout Texas including nine ER locations in the Houston area (Montrose, Houston Heights, Cypress/FM 1960, Copperfield, Memorial City, Westchase, Bellaire, Mission Bend/Sugar Land, and Stafford), Atascocita/Humble, Killeen, Austin, College Station/Bryan, Paris, Midland, Odessa, Texarkana, Spring, Plano, and Lewisville, TX.

Share article on social media or email:

Medico Sports Fashion GmbH Partners with Centric Software® for Centralized, Cross-Border Collaboration


Medico Sports Fashion GmbH Partners with Centric Software® for Centralized, Cross-Border Collaboration

Medico Sports Fashion GmbH Partners with Centric Software® for Centralized, Cross-Border Collaboration

With Centric PLM, we have equipped MEDICO for the future and can efficiently develop FILA, Tamaris and future brands to come.

German functional sportswear brand, Medico Sports Fashion GmbH (MEDICO), has selected Centric Software‘s Product Lifecycle Management (PLM). Centric Software provides the most innovative enterprise solutions to plan, design, develop, source and sell products such as apparel, footwear, sporting goods, furniture, home décor, cosmetics, food & beverage and luxury to achieve strategic and operational digital transformation goals.

MEDICO is part of the family-owned JCK group, and has stood for functional sportswear for over 100 years. The company became known internationally in the 1960s following its invention of a turtleneck ski jumper called the “ski-rolli”. Following numerous subsequent innovations, MEDICO is renowned worldwide as a leading product developer in the sport and outdoor segment.

Over the last 10 years, MEDICO has been awarded the license rights for FILA footwear, apparel and accessories across Continental Europe. The business now manages the collection development and production control of their joint venture suppliers in Bangladesh, as well as sales and building up the FILA distribution network in Europe. MEDICO has also recently been awarded the textile license for TAMARIS apparel and accessories. The new partnership begins with the spring/summer 2023 season.

Due to their association with FILA, a major international brand which has seen a huge comeback in recent years, in addition to developing TAMARIS and their own proprietary label, MEDICO soon found themselves drowning in offline, manual processes, such as Excel spreadsheets, PowerPoint presentations, design documents, contracts, emails and more. The company had to significantly ramp up their design and production processes to keep up with demand.

“We saw the need for greater product development and production standardization to shorten our lead time and meet market requirements. We wanted more reliable product information with fewer errors, and a way to eliminate our manual and decentralized ways of working,” says Medico.

In order to manage their processes more effectively, MEDICO made the decision to leave offline documents behind and enter the world of PLM. Their evaluation process was highly pragmatic and they reached out to Centric Software to find out how Centric’s out-of-the-box, cloud-integrated PLM solution could help to improve their workflows.

The benefits of adopting Centric PLM™ were immediately apparent, such as its intuitive and easy-to-use interface, and enabling teams to collaborate between the company HQ in Germany, the footwear division in the Netherlands and the offices in Far East and Turkey.

“We evaluated a few PLM solutions, but we chose Centric for its robustness, intuitiveness and flexible user interface. With Centric PLM we will be able to manage all our products including textiles and accessories as well as shoes on one centralized platform. We expect to see optimization of our time and resources, cutting down steps in our internal and external processes.”

MEDICO is now looking forward to the future with Centric and the ever-increasing ease and efficiency of having all product data combined in one easy to use solution.

“With Centric PLM, we have equipped MEDICO for the future and can efficiently develop FILA, Tamaris and future brands to come.”

“Centric Software is thrilled to partner with such a well-regarded German sportswear brand. We look forward to working with MEDICO to achieve their digital transformation goals and keep pace with the high demand for its products,” comments Chris Groves, President and CEO of Centric Software.

Learn more about Centric PLM

Request a Demo Medico Sports Fashion GmbH (http://www.medico.eu)

MEDICO has stood for functional sportswear for over 100 years. MEDICO became internationally known for its invention of a turtleneck ski jumper in the 1960s and is now a leading product developer in many sports areas.

On the basis of this long-standing experience, the MEDICO teams in Quakenbrück and Amsterdam now develop optimum solutions for sports brands such as FILA.

Share article on social media or email:

Marsai Martin Teams Up with the Foundation for Women’s Cancer to Raise Awareness of Gynecologic Cancer as Move4Her Celebrity Ambassador


News Image

“It’s an honor to partner with the Foundation for Women’s Cancer to help raise awareness and encourage women to prioritize their health by knowing how to recognize the signs and symptoms of gyn cancer in their own body and speak to their doctor about screening, treatment and care.” – Marsai Martin

The Foundation for Women’s Cancer (FWC) is pleased to announce that Marsai Martin, known for her roles in the ABC sitcom Black-ish and Universal’s Little, will be a Celebrity Ambassador for Move4Her. Now in its third year, Move4Her is the FWC’s primary fundraising event to power research and awareness of the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal or vulvar cancer. For the first time, this year Move4Her will be a Month of Movement held throughout September for Gynecologic Cancer Awareness Month.

“It’s an honor to partner with the Foundation for Women’s Cancer to help raise awareness and encourage women to prioritize their health by knowing how to recognize the signs and symptoms of gyn cancer in their own body and speak to their doctor about screening, treatment and care. This cause is a personal passion of mine because my grandmother fought a long, difficult battle with cervical cancer,” said Marsai Martin. “Every five minutes a woman is diagnosed with one of the five gynecologic cancers, but many women aren’t even aware of what the five types are before a diagnosis. We are challenging you to join us this September and move for five minutes each day to help raise funds that will make a difference in the future of gynecologic cancer care.”

“We are thrilled to partner with Marsai Martin, who is committed to sharing her personal family history with gynecologic cancer to encourage all women to put their health first,” said Ginger J. Gardner, MD, Chair, Foundation for Women’s Cancer, Gynecologic Cancer Surgeon and Vice Chair of Hospital Operations at Memorial Sloan Kettering Cancer Center. “One of the biggest barriers to early detection of gynecologic cancers is lack of awareness and we know that patient education is very important to help improve patient outcomes, and Marsai is using her platform to help change that in a meaningful way.”

Move4Her proceeds help fund crucial research, including the $50,000 FWC Move4Her Research Award awarded to a young investigator passionate about advancing treatment or care, as well as awareness initiatives such as Move the Message – FWC’s national campaign to increase awareness and drive early diagnosis of the five gyn cancers, especially among historically marginalized communities.

Register today at Move4Her.org to join the movement and participate in a virtual celebration at the end of the month with Marsai Martin – and other surprise guests – and the opportunity to connect by sharing stories and experiences. Visit Move4Her.com today to learn more, register and follow the FWC social platforms (Twitter, Instagram and Facebook) for exciting content all summer long. Let’s move the message and help spread the word about Move4Her!

ABOUT MOVE THE MESSAGE

Move4Her is an extension of Move the Message, a national campaign to increase awareness of gynecologic cancers, with a focus on historically marginalized communities and populations, such as brown and black women and those in rural areas, through dissemination of critical resources to drive earlier detection and diagnosis. These resources are easy to access at http://www.movethemessage.org for both the community at large as well as physicians to share with their patients.

Everyone can join #MoveTheMessage by taking five minutes to post an image or video of themselves in motion – walking, cycling, dancing – with the message, “#MoveTheMessage. 5 Cancers to Know. Take steps today to protect your tomorrows by visiting movethemessage.org” and tagging five people they know.

ABOUT THE SOCIETY OF GYNECOLOGIC ONCOLOGY

The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, SGO contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations. For more information, visit https://www.sgo.org.

ABOUT THE FOUNDATION FOR WOMEN’S CANCER

The Foundation for Women’s Cancer (FWC) is dedicated to increasing public awareness of gynecologic cancer risk, prevention, early detection, and optimal treatment. As the official foundation of the Society of Gynecologic Oncology (SGO), FWC is a 501 (c)(3) nonprofit organization that provides funding for gynecologic cancer research and training, as well as programs and resources. FWC has raised more than $60 million in areas such as research, awareness, education, and outreach. For more information, visit https://www.foundationforwomenscancer.org.

Share article on social media or email:



Get Ready for Back-to-School Season with Kyowa Hakko’s Cognizin® Citicoline


News Image

“When you are trying to juggle a million things at once, supporting your focus, mental energy and attention can make a big difference.”

With, Back-to-School season right around the corner, leading international health ingredient manufacturer Kyowa Hakko makers of Cognizin® Citicoline an innovative, pure, high-quality form of citicoline that is clinically studied to support brain health, mental energy, focus, and attention* is running informational TV “Newsbreaks”, starting August 1st, in key markets including NYC, Los Angeles, Chicago, Boston, and Dallas. Three of over 200 products containing Cognizin® are featured: Centrum’s Focus & Clarity, Solaray’s SharpMind Focus, and Nature’s Bounty Active Mind.

“Supporting our customers with consumer educational and informational initiatives is a key component of our continuing marketing efforts,” commented Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc., adding, “we partner with our customers from product development though to consumer awareness, it’s a win, win for everyone.

While hearing about “Back-to-School” may prompt delightful images of a fresh pack of crayons or an array of colorful folders, for many parents and teachers, it also brings a long list of tasks that have firm deadlines during August and September. Aside from collecting school supplies, parents have to coordinate updated paperwork, take the kids for a long-delayed haircut and get a replacement wardrobe for all the clothes that no longer fit. Not to mention the tedious task of labeling everything.

Jamie Hess, Wellness Mentor, and mom, speaks from firsthand experience saying that, “When you are trying to juggle a million things at once, supporting your focus, mental energy and attention can make a big difference.”

Danielle Citrolo, Pharm.D., Registered Pharmacist, Director of Scientific and Regulatory Affairs, Kyowa Hakko U.S.A., Inc. agrees that, “Focus and mental energy can play a big part in your productivity. Cognizin® Citicoline increases an important substance in the brain called phosphatidylcholine that supports healthy brain function.”

This science-backed solution works through supplying your brain with the energy it needs. “Essentially,” Danielle comments, “Cognizin® helps the neurons in your brain communicate better.”

Staying on top of the extensive preparation that comes with sending your child back to school can be an exhausting challenge. Cognizin® can fuel mental processes so you can stay in the zone instead of zoning out.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Cognizin® Citicoline

Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of Citicoline, a natural substance made endogenously in the body and especially vital to brain health.* Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, attention, and memory. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, pure and allergen-free. For more information on Cognizin®, visit Cognizin.com.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food products. For more information visit Kyowa-USA.com.

Share article on social media or email:

Three Mount Sinai Nursing Leaders to Be Inducted as Fellows in the American Academy of Nursing


“This honor would not have happened without the collaborative efforts of our entire nursing and education leadership at Mount Sinai. I hope to see more nurse leaders from Mount Sinai inducted in the future,” said Dr. Beth Oliver

Three Mount Sinai nurse leaders, including Chief Nurse Executive Beth Oliver, DNP, RN, have been selected to be Fellows of the American Academy of Nursing (AAN) in the 2022 Class of Fellows, a significant milestone for the most accomplished nurse leaders in education, management, practice, and research.

Dr. Oliver; Jared M. Kutzin, DNP, MS, MPH, RN, FSSH, Associate Professor of Emergency Medicine, and Medical Education, at the Icahn School of Medicine at Mount Sinai and Senior Director of the Simulation, Teaching, and Research (STAR) Center at The Mount Sinai Hospital; and Joan Miravite, DNP, RN, FNP-BC, Assistant Professor of Neurology at Icahn Mount Sinai and an expert in movement disorders, were among 250 nurses chosen by the Academy’s Fellow Selection Committee through a competitive and thorough application process. Fellows come from nearly 40 countries and hold a variety of roles within the nursing profession. Following their induction, fellows contribute their expertise by engaging with health leaders to improve the delivery of care, achieve health equity, and discover new innovations.

“To be inducted into the American Academy of Nursing is a great privilege and I’m very proud to be included with the fellow inductees of this class, especially my colleagues Drs. Kutzin and Miravite,” Dr. Oliver said. “This honor would not have happened without the collaborative efforts of our entire nursing and education leadership at Mount Sinai. I hope to see more nurse leaders from Mount Sinai inducted in the future.”

In her role as Chief Nurse Executive, Dr. Oliver is responsible for overseeing the practice of nursing and collaborating with the Health System’s senior executive team and the Chief Nursing Officers of Mount Sinai’s eight hospitals. Her top priorities include ensuring the safety and quality of care for patients, supporting and advancing the professional development of nurses, and transforming the care Mount Sinai provides around the needs of patients and communities.

Additionally, for more than 28 years, Dr. Oliver has been a transformational cardiac nurse leader at Mount Sinai. As Senior Vice President of Cardiac Services for the Health System, she leads cardiovascular service line strategy and operations while also being responsible for ensuring the delivery of quality care to Mount Sinai Heart patients. As a clinician, executive, and nurse, Dr. Oliver is committed to advancing population health to efficiently and comprehensively meet the needs of all patients and the current and future role of nurses in achieving this goal.

In addition to her Mount Sinai leadership roles, Dr. Oliver has led numerous cardiovascular health-related community outreach programs in partnership with the American Heart Association. In July 2018, Dr. Oliver was appointed President of the American Heart Association’s Board of Directors in New York City, the first nurse to hold the position.

Dr. Kutzin is an experienced educator, innovator, and simulationist. He is a Fellow in the Institute for Medical Education at Mount Sinai, a Fellow of the New York Academy of Medicine, and a Fellow of the Society for Simulation in Healthcare Academy. Dr. Kutzin serves on the Board of Directors for the Society for Simulation in Healthcare, on the New York State Emergency Medical Services Council, and on multiple curriculum revision committees for the Icahn School of Medicine. He has developed innovative curricula, including the use of virtual reality, for Emergency Medicine, Nursing, Critical Care, Family Medicine, Pediatrics, and departments across the Health System.

“I am honored to be chosen to join this distinguished academy of nurse leaders,” said Dr. Kutzin. “This is one of the greatest recognitions a nursing scholar can receive, and I’m thrilled to be sharing this with other Mount Sinai nurses. I look forward to joining this esteemed group of nurse leaders working to transform health care and health outcomes around the world.”

Dr. Miravite has more than 21 years of experience in the evaluation, programming, and management of deep brain stimulation (DBS) for Parkinson’s disease, essential tremor, and dystonia. She has helped to build a strong DBS program at Mount Sinai by educating physicians, nurse practitioners, students, and patients about DBS. Additionally, she is on the faculty at three academic institutions in New York City, including Icahn Mount Sinai. Dr. Miravite is the Chair-Elect of the American Academy of Neurology Consortium of Neurology Advanced Practice Providers. She also serves as core faculty for the Parkinson’s Foundation Team Training program, an international multidisciplinary training program for clinicians with the goal of improving treatment and outcomes for underserved patients with chronic neurologic conditions.

“This is an incredible recognition and I’m very proud to be included in this year’s class. I’d like to congratulate my fellow Mount Sinai inductees and thank you to the Academy, my mentors, and all of the individuals I’ve had the honor to work within the Department of Neurology who have led to me to this honor,” says Dr. Miravite.

Drs. Oliver, Kutzin, and Miravite join three other current Mount Sinai nurse leaders as fellows of the Academy: Fran Cartwright, PhD, RN-BC, AOCN, FAAN, Chief Nursing Officer and Senior Vice President at The Mount Sinai Hospital and Mount Sinai Queens; Maria Vezina, EdD, RN, NEA-BC, FAAN, Vice President and Chief of Nursing Practice, Education, and Advanced Practice Nursing Credentialing; and Toby Bressler, PhD, RN, OCN, FAAN, Senior Director of Nursing for Oncology and Clinical Quality and Assistant Professor Medical Oncology at Icahn Mount Sinai.

The 2022 Academy Fellows will be recognized for their contributions in health care at the Academy’s annual Health Policy Conference, taking place on Thursday, October 27, through Saturday, October 29. The induction ceremony will be held on October 29 at 5:30 pm at the Marriott Marquis in Washington, D.C.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter, and YouTube.

TexPTS and SMASA Partnership Bolsters Sports Physical Therapy Management and Operations


News Image

“This partnership will allow the expansion of sports medicine and orthopedic specialists to advance cutting edge treatment strategies and emerging surgical techniques. We are now poised for growth and success in the decades to come.” – Dr. Paul Saenz, SMASA’s Chairman of the Board of Directors

Sports Medicine Associates of San Antonio (SMASA), a team of Board-certified orthopedic surgeons and sports medicine primary care physicians committed to providing quality care, is proud to announce their joint venture with Texas Physical Therapy Specialists (TexPTS). This venture solidifies TexPTS’ operations of 4 SMASA physical therapy clinics and SMASA’s 7 total locations, further expanding the groups’ footprint across San Antonio, Austin and greater Texas.

This venture will allow SMASA to maintain its existing brands while gaining access to TexPTS’ parent company’s, Confluent Health, ecosystem of management services, education, and musculoskeletal health innovations. These services include efficient community outreach, digital innovations, value-based care pathway models, marketing and finance tools, best in brand physical therapy partnerships including the PTPN network, as well as continuing education programs and staff development opportunities such as Evidence In Motion, a nationally recognized residency, Fellowship, and certification education provider in physical and occupational therapy programs.

“Having joined forces with a new teammate in providing sports medicine care for San Antonio and South Texas, we believe that our union with Texas Physical Therapy Specialists and Confluent Health will allow us to become leaders in innovation for providing sports medicine health care, both surgical and nonsurgical, to all San Antonio and South Texans that want to remain physically active,” said Dr. Bob Girling, MD, renowned orthopedic surgeon and partner of SMASA. “We feel, that with the like minds we have joined, the sky’s the limit.”

In response to this joint venture, and in anticipation of continued growth, TexPTS has appointed Dr. Adam Roggia, PT, MS, MBA, OCS to serve as Chief Executive Officer of all SMASA locations. Roggia previously served as Director of TexPTS – SMASA and will now be running all operations for the venture.

SMASA will continue to offer the same programs in clinic as well as maintain their long standing relationships as the Medical Team of the San Antonio Spurs, San Antonio FC, Texas A&M San Antonio, Trinity University, St. Mary’s University, Schreiner University, and San Antonio high schools. SMASA has served as the official sports medicine team for the Spurs program for over 25 years.

“SMASA is very pleased to announce its formal engagement with Texas Physical Therapy Specialists and Confluent Health as its strategic partner for growth, development and innovation in the south Texas community,” said Spurs team physician and SMASA’s Chairman of the Board of Directors, Dr. Paul Saenz, D.O. “This partnership will allow the expansion of sports medicine and orthopedic specialists to advance cutting edge treatment strategies and emerging surgical techniques. We are now poised for growth and success in the decades to come.”

To learn more about SMASA and TexPTS’ sports and orthopedic services please visit http://www.texpts.com. For more information on SMASA, please visit http://www.sportsmedsa.com.

###

About Texas Physical Therapy Specialists

Texas Physical Therapy Specialists (TexPTS) is a Texas-based, private physical therapy practice group. As a proud member of the Confluent Health family, TexPTS positively impacts patients’ lives by delivering the best care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. For more information, visit texpts.com, or find them on Facebook at @texpts.

About Confluent Health

Confluent Health is a family of physical and occupational therapy companies. We are transforming healthcare by strengthening private practices, developing highly effective clinicians, innovating new services and technology to improve the quality of care for patients, and lowering costs via more effective treatment, workplace wellness, and injury prevention. For more information, visit goconfluent.com or find us on Facebook at @confluentfamily.

About Sports Medicine Associates of San Antonio

Sports Medicine Associates of San Antonio is a Texas-based, private Sports Medicine and Orthopedic Surgery Group. We have served San Antonio community and set the standard of high quality, expert medical and sports medical care. We seek to expand our impact by innovating and improving the quality of care for patients. Any Athlete, Any Injury, Any Time. For more information, visit sportsmedsa.com or find us on Facebook at @sportsmedicineassociates.

Share article on social media or email:

STIGMA Launches Mobile App to Expand Conversations Around Mental Health


News Image

STIGMA, the mental health startup that uses video storytelling to normalize conversations about mental health, today announced the launch of its native app available to download for free in both the App Store and Google Play. Through asynchronous text, audio, and video messages, the app connects people with others who share their lived experiences to exchange messages of HOPE.

“People aren’t comfortable talking about their mental health,” says Ariana Alejandra Gibson, CEO and founder of STIGMA, who personally lives with anxiety disorder, panic attacks and is the daughter of a father with schizophrenia. “A devastating repercussion of this is that the average time between someone experiencing their first symptom of mental illness and first seeking treatment is 11 years. We believe we can meaningfully lower this number by offering people safe spaces to practice talking about their mental health and easy ways to connect with others who are looking to do the same.”

The global mental health app market is expected to reach $17.5 billion dollars by 2030, yet many solutions in today’s market are focused on creating better experiences for people already in treatment. STIGMA is focused on attracting the 60-80% of people with treatable mental illness who don’t seek treatment by helping them get on a path to healing more quickly. “We’re not a replacement for treatment or therapy,” says Gibson. “We’re a place to find social connection and develop the vulnerability required to successfully ask for help.”

“STIGMA has found a way to get more people involved in the conversations surrounding mental health,” says Steven Galanis, CEO and co-founder of Cameo and one of STIGMA’s first investors. “Every day at Cameo we see the positive impact human connection has on the people who invite us to join them in the celebratory moments of their lives. What impressed me about STIGMA is how quickly Ariana and her team created a brand that people trust enough to invite into the harder moments of life. I think STIGMA is going to shatter taboos surrounding mental health because they’re using the way people like to communicate and applying this to a topic that can be hard to talk about.”

Following this launch, STIGMA will be focused on expanding its partnerships with behavioral and mental health providers with the goal to offer patients’ another tool in their mental health toolkits that can be used in between sessions and in the exact moment of need. Additionally, the company will continue to be the safest place online to talk about mental health by moderating every message before it’s shared.

“People are looking for safe places to talk about their mental health,” says Gibson. “Recent research we conducted found that while 78% of people said they’d be there to support a friend or family member who was struggling, 70% felt they themselves had no one to talk to about their mental health when they needed support. Our respondents overwhelmingly said they’re looking for someone who understands and shares their lived experience.”

The iOS app is available to download in the App Store, and the Android app is available to download via Google Play today. Users can search “the STIGMA app” in the App store to download it.

About STIGMA

STIGMA is a mental health startup that uses video storytelling to normalize conversations about mental health. In addition to capturing and sharing personal stories from people who share what it’s like to live with mental illness and other misunderstood conditions, they offer an online community where members can ask for and offer messages of HOPE via asynchronous video, audio, and text message. STIGMA is backed by LongJump, SSC Venture Partners, Mike Gamson, Steven Galanis and other notable angels. For more information please visit https://www.thestigma.app/.

Share article on social media or email:

Amprion Announces Research Collaboration With Mayo Clinic To Further Understand Rapidly Progressive Dementia


News Image

“This study will help us gain valuable insights to advance the molecular understanding of this highly elusive, complex, and devastating neurological condition.” Amprion CEO Russ Lebovitz, MD/Ph.D.

Amprion is pleased to announce a research collaboration with Mayo Clinic in Florida to investigate biomarker utility within the cerebrospinal fluid (CSF) from patients with Rapidly Progressive Dementia (RPD).    

In a collaboration called “Prospective Measures of Outcome in Rapidly Progressive Dementia,” Amprion will perform the SYNTap® Biomarker Test on a mixed cohort of approximately 200 CSF samples from well-characterized, clinically diagnosed RPD patients and healthy controls. This research is expected to shed light on the role alpha-Synuclein (αS), a misfolded protein, plays in the neurodegenerative condition of RPD.

“We’re excited to participate in this scientific collaboration with Mayo Clinic in Florida to explore the biomarker influence of misfolded Synuclein associated with RPD,” Amprion CEO Russ Lebovitz, MD/Ph.D., remarks. “This study will help us gain valuable insights to advance the molecular understanding of this highly elusive, complex, and devastating neurological condition,” added Dr. Lebovitz.

This collaboration aims to define further the characterization, clinical evaluation, and underlying synucleinopathy in RPD. In doing so, we aim to improve the diagnostic strategies to serve this patient population better.

Amprion will attend AAIC in San Diego (7/31-8/4), and we look forward to connecting with medical professionals during this conference. Visit us at booth #305 for collaborative exchange.

ABOUT AMPRION

A leader in Prion Detection Science™, Amprion innovates biomarker testing for brain diseases. Our SYNTap® Biomarker Test helps doctors diagnose Lewy Body Variant of Alzheimer’s Disease, Parkinson’s Disease, and Lewy Body Dementia. Amprion strives to accelerate precision medicine for neurodegenerative diseases through molecular testing.

Share article on social media or email: